Overview

High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia

Status:
Completed
Trial end date:
2001-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of high-intensity, brief-duration chemotherapy in treating patients with relapsed or refractory acute lymphocytic leukemia.
Phase:
Phase 2
Details
Lead Sponsor:
Comprehensive Cancer Center of Wake Forest University
Wake Forest University Health Sciences
Collaborator:
National Cancer Institute (NCI)
Treatments:
Cobalt
Cortisol succinate
Cyclophosphamide
Cytarabine
Dexamethasone
Doxorubicin
Etoposide
Hydrocortisone
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Hydrocortisone hemisuccinate
Ifosfamide
Leucovorin
Levoleucovorin
Liposomal doxorubicin
Methotrexate
Vincristine